The potential use of stem cells derived from human amniotic fluid in renal diseases  by Noronha, Irene L. et al.
The potential use of stem cells derived from human
amniotic fluid in renal diseases
Irene L. Noronha1, Rita C. Cavaglieri1,2, Felipe L. Janz2, Sergio A. Duarte3, Marco A.B. Lopes3,
Marcelo Zugaib3 and Sergio P. Bydlowski2
1Laboratory of Cellular, Genetic, and Molecular Nephrology, Faculty of Medicine, University of Sa˜o Paulo, Sa˜o Paulo, Brazil; 2Laboratory
of Genetic and Molecular Hematology, Faculty of Medicine, University of Sa˜o Paulo, Sa˜o Paulo, Brazil and 3Department of Obstetrics
and Gynecology, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
Amniotic fluid (AF) contains a variety of cell types derived
from fetal tissues that can easily grow in culture. These cells
can be obtained during amniocentesis for prenatal screening
of fetal genetic diseases, usually performed during the
second trimester of pregnancy. Of particular interest,
some expanded sub-populations derived from AF cells are
capable of extensive self-renewal and maintain prolonged
undifferentiated proliferation, which are defining properties
of stem cells. These human AF stem cells (hAFSCs) exhibit
multilineage potential and can differentiate into the three
germ layers. They have high proliferation rates and express
mesenchymal and embryonic markers, but do not induce
tumor formation. In this study, hAFSCs derived from
amniocentesis performed at 16–20 weeks of pregnancy were
isolated, grown in culture, and characterized by flow
cytometry and by their potential ability to differentiate into
osteogenic, adipogenic, and chondrogenic lineages. After 4–7
passages, 5 105 hAFSCs were inoculated under the kidney
capsule of Wistar rats that were subjected to an experimental
model of chronic renal disease, the 5/6 nephrectomy model
(Nx). After 30 days, Nx rats treated with hAFSCs displayed
significant reductions in blood pressure, proteinuria,
macrophages, and a-smooth muscle actin expression
compared with Nx animals. These preliminary results suggest
that hAFSCs isolated and expanded from AF obtained by
routine amniocentesis can promote renoprotection in the
Nx model. Considering that the AF cells not used for fetal
karyotyping are usually discarded, and that their use does not
raise ethical issues, they may represent an alternative source
of stem cells for cell therapy and regenerative medicine.
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Stem cells (SCs) represent a potential and attractive cellular
therapy for renal diseases. A large amount of research in this
area has been provided through the use of adult stem cells,
particularly mesenchymal SCs (mSCs). The main sources of
mSCs include bone marrow (BMmSCs), peripheral blood
umbilical cord blood, and other mesenchymal tissues, such as
adipose tissue. The use of adult mSCs has some drawbacks
and limitations. Besides the low number of mSCs that are
available in the adult BM, which declines with increasing age,
mSCs expand slowly and have a restricted differentiation
potential.1 Pluripotent embryonic SCs have the potential to
differentiate into a wide range of cell types, but their use in
renal therapies involves ethical and technical problems,
particularly the high risk of immunological rejection,
teratoma formation, and carcinoma development.
An alternative source of SCs that has potential clinical
therapeutic applications is amniotic fluid (AF). It is well
known that AF contains various cell types, derived from
embryonic and extra-embryonic tissues.2,3 Human AF cells
can be easily obtained during amniocentesis for prenatal
diagnosis of fetal chromosomal abnormalities, routinely used
in the last seven decades, with low risk for the mother and the
fetus. For the screening of fetal genetic diseases, amniocent-
esis is usually performed during the second trimester, at
16–20 weeks of pregnancy. Amniotic fluid cells grow easily in
culture. Of particular interest, some expanded sub-popula-
tions derived from AF cells are capable of extensive self-
renewal and maintain prolonged undifferentiated prolifera-
tion, which are defining properties of SCs,4 and are termed
human amniotic fluid stem cells (hAFSCs). The fetal origin
of these cells collected from AF and cultured in vitro has been
confirmed by human leukocyte antigen typing and by the
identification of Y chromosome in the AF obtained by amnio-
centesis of mothers who are pregnant with male children.
CHARACTERISTICS OF AMNIOTIC FLUID CELLS
Amniotic fluid contains a wide variety of different cell types
and properties that are mainly derived from fetal tissues.3
From the first trimester of pregnancy until the middle of the
second trimester, AF is mostly formed by the passive
movement of water through the fetal skin and amniotic
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membrane, as a result of simple diffusion and active trans-
port of sodium and chloride, and is considered to be an
ultrafiltrate of maternal blood. In this period, amniotic cells
are derived from the sloughing of the yolk sac, fetus,5
placenta,6,7 and amnion.3,4,6–8
Between the 17th and 20th week of gestation, keratiniza-
tion of the fetal skin occurs, and most of the AF is composed
of fetal urine9 and, to a minor extent, is derived from the fetal
respiratory10 and digestive tracts.11 As a result of fluid
dynamics, the cells in the AF are mainly derived not only
from the urinary tract but also from respiratory and
gastrointestinal tracts.
Amniotic fluid cells obtained by amniocentesis grow
rapidly in routine culture. The adherent AF cells can be
classified into three groups based on their morphological,
biochemical, and growth characteristics: epithelioid E-type
cells, AF-specific AF-type cells, and fibroblastic F-type cells.
The epithelioid E-type cells (likely derived from the fetal
skin) and the AF-specific AF-type cells (which produce
estrogen, chorionic gonadotropin, and progesterone, and are
likely derived from placental trophoblast tissue) are found in
the initial passages of cultivation. The fibroblastic F-type cells
(derived from fetal mesenchymal tissue and dermal fibro-
blasts) are adherent cells and exhibit characteristics of rapid
proliferation with phenotypes and multilineage differentia-
tion similar to BMmSCs.3–5,12,13
The adherent human AF cells expanded in culture have
been extensively characterized by flow cytometry. Similar to
BMmSCs, they express CD29, CD44 (hyaluronan receptor),
CD73, CD90, CD105 (endoglin), CD166, and human
leukocyte antigen class I, but not human leukocyte antigen
class II.4,14–16 They are multipotent cells, capable of
differentiating into a variety of cell types including,
adipogenic, osteogenic, and chondrogenic lineages.4,14,15,17,18
Owing to these characteristics, these cells are usually termed
human AF mSCs (hAF-mSCs).4,14,15,17,18
Aside from mesenchymal markers, hAFSCs simulta-
neously express markers associated with pluripotency, such
as Oct-4 (an embryonic SC marker), Nanog protein
(responsible for pluripotency), and stage-specific embryonic
antigen-4, which are specific markers of human embryonic
cells.15,19 Indeed, hAFSCs express genes characteristic of
endodermal, mesodermal, and ectodermal germ layers,20 and
exhibit, under specific culture conditions, the potential to
differentiate into neuronal, myogenic, and hepatogenic cell
lineages.15,18,21
Similar to the embryonic SCs that exhibit telomerase
activity, hAFSCs also have high levels of telomerase.
Telomerase activity protects against the progressive shortening
of chromosomal telomeres, protecting against senescence.
hAF-mSCs have significantly greater telomere length compared
with BMmSCs,17,22 providing them a great proliferative
capacity. In fact, hAFSCs have a high expansion rate in vitro,
with a proliferative rate in culture greater than adult mSCs.
Although hAFSCs have a marked high proliferative and
differentiation capacity, they do not undergo neoplastic
transformation in vitro17 or induce teratoma transformation
similar to embryonic SCs. Accordingly, hAFSCs are not
tumorigenic in vivo. Injections of hAF-mSCs into immuno-
deficient animals does not induce tumor formation,17 which
is an additional advantage for their eventual clinical use in
regenerative medicine.
Atala et al.23 isolated a sub-population of c-kit (CD117)-
positive SC from AF cells, which represents about 1% of the
total AF cell population. CD117 (the receptor for SC factor)
is a cell surface marker expressed on human embryonic SCs,
pluripotent hematopoietic progenitor cells, mast cells, and
other somatic SCs. c-Kitþ cells can be immunoselected from
AF and expanded in culture as a clonal cell line. They express
the transcription factor Oct-4 and have the potential to
differentiate into the three germ layers24 and form embryoid
bodies.25 They also express surface markers characteristic of
mSCs, including CD29, CD44, CD73, CD90, and CD105, and
differentiate into adipogenic, osteogenic, myogenic, endothe-
lial, neurogenic, and hepatic lineages. This fetal pluripotent
lineage has a high proliferation rate with a doubling time
ofB36 h. c-kitþ hAFSCs do not induce tumor formation in
mice.24
hAFSCs AND THE KIDNEY
Perin et al.26 analyzed the effect of c-kitþ hAFSCs on kidney
differentiation by injecting these cells into isolated murine
embryonic kidneys. After 10 days, histological analysis and
live imaging showed that hAFSCs transfected with green
fluorescent protein and Lac-Z integrated into kidney
structures, including the tubules and developing nephrons.26
A possible role for hAFSCs in renal differentiation was
provided by the marked expression of human zona
occludens-1, claudin, and glial-derived neurotrophic factor
within the developing kidney.26 Further evidence for the
contribution of c-kitþ hAFSCs in renal differentiation was
recently provided by Siegel et al.27 by cultivating labeled
hAFSCs mixed with murine embryonic kidneys that had been
dissociated into single cells. An analysis of the chimeric
aggregates showed hAFSCs within the structures expressing
PAX-2, E-cadherin, calbindin, Wt1, and laminin, which are
markers found in renal structures.27
The potential ability of hAFSCs to undergo mesenchymal-
to-epithelial transition was also demonstrated by the sequen-
tial cultivation of hAFSCs with epidermal growth factor/
platelet-derived growth factor, and fibroblast growth factor-4/
hepatocyte growth factor, which induced the expression of
the epithelial markers CD51 and human zona occludens-1,
and the podocyte markers CD2AP and NPHS2.28 Recently,
Da Sacco et al.20 found different expression levels of the renal
markers nephrin, human zona occludens-1, PDGF-areceptor,
glial-derived neurotrophic factor, aquaporin-1, PAX-2,
LIM-1, occludin, tyrosine kinase A, E-cadherin, CD24, and
OB-cadherin in AF cells obtained by amniocentesis between
15 and 20 weeks of pregnancy and cultured for 4–5 passages.
Given that the AF in this period of gestation mostly consists
of fetal urine, the cells with this renal marker expression
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profile in the AF are likely derived from the fetal kidney
structures. Moreover, in this study, a specific AF cell
population of nephron precursors characterized by the co-
expression of CD24 and OB-cadherin (markers that are also
expressed in the metanephric mesenchyma) was expanded in
culture. On the basis of the expression of nephrin and
podocalyxin (markers of podocytes), PDGF-areceptor (me-
sangial cell marker), E-cadherin (METmarker), and tyrosine
kinase A (stromogenic cortical mesenchymal cell marker),
five sub-populations of renal progenitor cells could be
identified in the AF.
The effect of hAFSCs administration in an experimental
model of acute kidney injury has already been analyzed. Perin
et al.29 showed that the intra-renal injection of c-kitþ
hAFSCs into the glycerol-induced rhabdomyolysis model of
acute tubular necrosis ameliorated kidney injury, as demon-
strated by decreased blood urea nitrogen and creatinine
levels, and provided protection against tubular structural
damage cast formation. The protective effect of c-kitþ
hAFSCs administration was possibly related to an induction
of cellular proliferative activity and a significant decrease in
apoptosis. Additional renoprotection might have been
obtained by the induction of immunomodulatory effects,
characterized by a decrease in proinflammatory cytokines
and an increase in anti-inflammatory cytokines, facilitating
the control of local immune responses.29
INFUSION OF hAFSCs INTO AN EXPERIMENTAL MODEL
OF CHRONIC RENAL DISEASE
We and others have shown the beneficial effects of BMmSCs
in experimental models of chronic progressive nephropathy,
such as the remnant kidney model.30,31 We are currently
analyzing the potential therapeutic use of hAF-mSCs in an
experimental model of chronic kidney disease by analyzing
the administration of hAF-mSCs versus BMmSCs to the 5/6
nephrectomy model (Nx).
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Figure 1 |The capacity of human amniotic fluid stem cells (hAFSCs) to differentiate into osteogenic, adipogenic, and chondrogenic
lineages. (a) In culture, hAFSCs have fibroblast-like morphology. (b) Adipogenic differentiation was evaluated using Oil Red O staining.
Cytoplasmic lipid droplets appear red ( 400). (c, d) Osteogenic differentiation was confirmed by Alizarin red and alkaline
phosphatase staining. Calcium deposits and alkaline phosphatase activity appear red ( 100 and  400, respectively). (e, f) Chondrogenic
differentiation was confirmed by hematoxylin and eosin and immunofluorescence staining using specific monoclonal antibodies
against type II collagen ( 200 and  400, respectively).
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For this study, AF cells from second-trimester amniocent-
esis (16–20 weeks of gestation), recommended by advanced
maternal age, were obtained at the Clinical Hospital of the
University of Sa˜o Paulo for prenatal diagnosis of fetal genetic
mutations. The first sample was discarded because of the risk
of contamination with maternal cells. The second aspirated
sample consisted of approximately 30ml of AF and was
divided into two samples, one (20ml) was processed for
fetal karyotyping and the other (10ml) for the study. Only
karyotypically normal cases were included in this study. The
study protocol was approved by the Local Ethics Committee
(0414/2007), and all of the participants signed a written
informed consent.
The AF cells, after centrifugation, were placed into a
culture flask with a-minimum essential Eagle’s medium
(Gibco Division, Invitrogen, Carlsbad, CA) supplemented
with 20% fetal bovine serum (Gibco), 100U/ml of penicillin,
and 100 mg/ml of streptomycin.
After 72 h, the non-adherent AF cells in the supernatant
were removed, and the cells that adhered to the plastic culture
flasks were expanded. After reaching 70% confluence, they
were detached with trypsin/ethylenediaminetetraacetic acid.
The cells exhibited fibroblast-like and spindle-shaped
morphologies (Figure 1a).
The cells were phenotypically characterized by flow cyto-
metry using fluorescein isothiocyanate- or phycoerythrin-
conjugated antibodies. The adherent AF-SCs were positive
for the surface markers that are characteristic of mSCs
(CD29: 98.0±0.6%, CD44: 96.8±1.0%, CD90: 67.0±3.0%,
and CD105: 89.9±4.7%). Only a small percentage of the
hAFSCs expressed CD45 (2.1±0.7%, hematopoietic lineage),
CD34 (1.3±0.2%, (hematopoietic SC), CD117 (1.5±0.3%,
c-kit), and CD31 (1±0.2%, endothelial cells; Figure 1).
The hAFSCs were further characterized on the basis of
their multipotent potential for osteogenic, adipogenic, and
chondrogenic differentiation, as revealed by positive staining
for Alizarin red, alkaline phosphatase, Oil Red O, and
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Figure 2 | Surface antigen evaluation by flow cytometry. The human amniotic fluid stem cells (hAFSCs) were positive for CD29,
CD44, CD90, and CD105; and negative for CD14, CD31, CD34, CD45, and CD117. IgG1-fluorescein isothiocyanate (FITC) and IgG2-phycoerythrin
(PE) antibodies were used as isotype controls.
Table 1 | Clinical, biochemical, and histological parameters of
Nx rats and the controls, which received BMmSCs or hAFSCs
Blood
pressure
(mmHg)
Urinary
protein
(mg/24 h)
Serum
creatinine
(mg/dl)
Glomerulo-
sclerosis
index (%)
Sham 123±3 10.9±1 0.46±0.03 0.3±0.3
Sham+BMmSCs 132±4 7.7±1 0.27±0.05 1.9±1.1
Sham+hAFSCs 119±6 9.8±2 0.54±0.03 3.6±2.7
Nx 185±4a,b,c 92.9±14a,b,c 1.05±0.15a,b,c 26.3±5.5a,b,c
Nx+BMmSCs 162±7a,b,c,d 31.9±6f 0.62±0.09d 5.4±2.4e
Nx+hAFSCs 152±5a,c,f 39.5±12e 0.74±0.08c 5.2±4.5e
Abbreviations: BMmSCs, bone marrow mesenchymal stem cells; hAFSCs, human
amniotic fluid stem cells; Nx, 5/6 nephrectomy model.
Data are presented as mean±s.e.m.
aPo0.01 versus sham.
bPo0.01 versus sham+BMmSCs.
cPo0.05 versus sham+hAFSCs.
dPo0.05 versus Nx.
ePo0.01 versus Nx.
fPo0.001 versus Nx.
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hematoxylin, eosin, and immunofluorescence for type II
collagen (Figure 2). In addition, RT-PCR experiments demon-
strated that these hAFSCs express Oct-4 4/5 and NANOG.
To investigate the effects of hAF-mSCs on an experimental
model of chronic progressive renal disease, hAFSCs were
administered to rats subjected to the remnant kidney model.
This was compared with an infusion with rat BMmSCs, as
previously described.30 Male Wistar rats (n¼ 44) were
subjected to a Nx or sham operation. hAF-mSCs (5 105
cells) or BMmSCs (5 105 cells) at the fourth to seventh
cellular passage were inoculated into the kidney subcapsule
and the rats were observed by 30 days. The animals
were subdivided into six groups: S, sham-operated rats
(n¼ 5), Sþ hAFSCs (n¼ 6), sham rats receiving hAFSCs;
SþBMmSCs (n¼ 5), sham rats receiving BMmSCs; Nx
(n¼ 9), rats subjected to Nx; Nxþ hAFSCs (n¼ 8), Nx rats
receiving hAFSCs, and NxþBMmSCs (n¼ 11), Nx rats
receiving BMmSCs. The following parameters were analyzed:
blood pressure, urinary protein excretion, serum creatinine,
and the glomerulosclerosis index. In addition, kidney
infiltration of ED1þ cells (macrophages; M), CD43þ cells
(lymphocytes), and a-smooth muscle actin (myofibroblasts)
was analyzed by immunohistochemistry.
The inoculation of hAFSCs into the kidney subcapsular
region of rats subjected to a Nx induced renoprotective
effects, characterized by a significant reduction in blood
pressure, urinary protein excretion, and the percentage of
glomerulosclerosis, similar to the results observed after the
administration of BMmSCs (Table 1). However, the marked
effect of hAFSCs in reducing the percentage of a-smooth
muscle actin, which identifies myofibroblasts, is of relevance,
considering that they are the effector cells of renal fibrogen-
esis and that myofibroblast infiltration correlates with the
progression of renal disease (Table 2).
A significant reduction in the number of macro-
phages was also observed in the Nx animals that received
hAFSCs, whereas the BMmSCs inoculation was not asso-
ciated with this cellular effect in this model. In addition, the
administration of hAFSCs induced a significant increase in
the number of lymphocytes in the kidney reflecting an
ongoing in situ immune response, particularly in the cases
transplanted with hAFSCs (Table 2). The characterization of
the lymphocyte subsets, cytotoxic mediators, and cytokine
production profile will help characterize this pattern of the
immune response. Previous studies using a similar model of
discordant cellular xenotransplantation reported the presence
of an inflammatory infiltrate in the myocardium, suggestive
of acute rejection in both immunocompetent rats (with or
without immunosuppression) and athymic rats.32
A pertinent issue in the field of cell therapy is defining to
what extent the presence of an inflammatory infiltrate can
be regarded as definitive evidence of rejection. BMmSCs have
previously been shown to have immunosuppressive and
immunoregulatory properties. The low expression of class II
major histocompatibility complex molecules and the absence
of co-stimulatory molecules may contribute to their
roles as immunoprivileged cells, allowing them to escape
the recognition of alloreactive cells.33,34 The immuno-
regulatory effects may also rely on their ability to induce
the production of anti-inflammatory cytokines and growth
factors35 and generate CD4þ CD25þ regulatory T cells.36
Thus, the presence of an inflammatory infiltrate does not
represent evidence for allograft rejection.
In conclusion, these preliminary results suggest that
hAFSCs that are successfully isolated and expanded from the
AF obtained by routine amniocentesis can promote renopro-
tection in the Nx model. Considering that the AF cells not used
for fetal karyotyping are usually discarded, and that their use
does not raise ethical issues, they may represent an alternative
source of SCs for cell therapy and regenerative medicine.
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